Developing Skincare Boosters: Spicules, Safety Assessment, and Claims

Developing Skincare Boosters: Spicules, Safety Assessment, and Claims

June 5, 2026

8

Jorit Tessmann

Jorit Tessmann

CEO & Founder at Labtree GmbH

A skincare booster is a skincare product that is not intended to work alone, but rather in conjunction with other products: as a pre-treatment before a serum, as a concentrate to be mixed into a cream, or as a layer beneath the next step in the skincare routine. For product development, this means that the formulation, safety assessment, and claims must cover the combination, not just the individual product. A booster that actually alters the absorption of subsequent products also alters their exposure.

This article classifies the different types of boosters available, identifies the boundary between them and injectable skin boosters, explains what spicule boosters do from a technical standpoint, and outlines the testing and claims required for a booster system in the EU.

The topic is short and compact

A skincare booster must work in combination, which is why the intended follow-up products belong in the briefing, sampling, and safety assessment.

In preclinical studies, spicules from Haliclona sp. remained in the skin for more than 48 hours and can also enhance the absorption of other substances applied afterward.

Injectable skin boosters are not cosmetic products; a topical booster must not suggest the effects of a medical treatment.

For spicule suspensions, yield point, meterability, and homogeneity during filling determine batch consistency.

Booster claims are comparative and require proof of the combination with and without the booster; studies from the raw material supplier are usually not sufficient for this.

So läuft die Entwicklung bei Labtree

1

Konzeptionierung

2

Bemusterung – Standardmuster in 24 h

3

Individualisierung

4

Prototyping

5

Produktion

White Label 2–3 Monate · Private Label 3–6 Monate · Produktion ab 1.000 Stück

What types of skincare boosters are there?

Under the term booster, three technically distinct product types exist in the market. They differ in when and how they interact with the subsequent product, and precisely that determines the development effort.

  • Pre-treatment: a product applied before the actual skincare routine that alters the skin surface, such as a spicule booster containing needle-shaped sponge spicules made of silica.

  • Concentrate for mixing: a few drops of an active ingredient concentrate added to a cream or serum. The actual blended product is only created upon application.

  • Primer layer: a lightweight serum applied beneath the next product, such as a PDRN primer before an active ingredient serum.

Commercially, boosters are attractive for brands because they complement the existing portfolio instead of replacing an existing step. This represents a typical range extension. Technically, it is the more demanding category: a serum must work on its own; a booster must additionally work with products whose formulation the brand might not even know. How spicule technology functions in the formulation is described in the article on Sponge Spicules.

Cosmetic Booster or Skin Booster: Where Is the Line Drawn?

A booster is only a cosmetic product if it is applied externally. According to paragraph 1, point (a), the definition in Art. 2 Regulation (EC) No 1223/2009 covers substances and mixtures intended to come into contact externally with the skin, hair system, nails, lips, or external intimate regions. According to paragraph 2, substances or mixtures intended to be injected or implanted into the body are explicitly not considered cosmetic products. Injectable skin boosters from aesthetic medicine therefore do not fall under the Cosmetics Regulation, even if they share the same name in marketing.

For product development, this boundary has two consequences. First, a topical booster must not be advertised as replacing a treatment: Art. 20 (1) of the Regulation prohibits texts, names, and images that imply characteristics or functions which the product does not have. Second, anyone using the term skin booster in the product name should determine early in the claim concept how the differentiation from injection is communicated. This applies equally to labels, websites, and retailer texts.

Spicules and the image of microneedling

Spicule boosters are often advertised with a microneedling effect. The formulation remains an externally applied mixture, but the statement about a needle-like effect is a functional claim that must be substantiated on the finished product. The section on advertising claims shows what evidence can be considered for this.

What do spicules do to the skin?

Spicules are needle-like skeletal elements derived from sponges, chemically predominantly composed of silica. In the formulation, they act as dispersed microneedles: they mechanically disrupt the stratum corneum, thereby opening a pathway for subsequently applied substances. The scientific evidence is predominantly preclinical and originates from pharmaceutical research, yet it provides clear indications of the magnitude of the effect.

  • Dwell time: Spicules from Haliclona sp. disrupt the skin in a dose-dependent manner and, according to earlier work by the same research group, remain in the skin for over 72 hours (Zhang et al. 2021, Pharmaceutics).

  • Enhancement: In the same study, the flux of insulin as a hydrophilic model peptide through porcine skin in vitro increased from 5.0 to 457.0 ng/cm² per hour, roughly 90 times that of passive penetration.

  • Shape matters: A comparison of spicules from five sponge species showed that the enhancement of permeation correlates with the aspect ratio (length-to-diameter ratio): the more slender the needle, the lower the enhancement. Spicule raw materials are therefore not interchangeable at will.

  • Duration of the effect: According to this study, the microchannels created by a dermaroller close within about 20 minutes, whereas the embedded spicules remained in the skin for over 48 hours in the experiment, keeping the pathway open correspondingly longer.

The data originate from in vitro experiments on porcine skin and in vivo studies on rats and mice using pharmaceutical active ingredients and cannot be directly translated to a finished cosmetic product. Nevertheless, one point is crucial for product development: because the disruption of the stratum corneum is mechanical rather than substance-specific, it must be assumed that an effective spicule booster increases not only the absorption of the intended active ingredient, but also that of other substances applied in the following hours. This can include preservatives, fragrances, and active ingredients from products of other brands. For the raw material, this also means that the length distribution and breakage rate of the spicules are specification parameters that can vary between supply batches and should be tested upon incoming goods inspection.

What does the safety assessment of a booster system need to cover?

The safety assessment must cover use in combination if, according to the instructions for use, this is part of normal or reasonably foreseeable use. According to Art. 3 and Annex I of Regulation (EC) No 1223/2009, cosmetic products must be safe under such use. Part A No. 6 of the safety report requires exposure data on the site of application, amount, duration, and frequency, as well as on normal and reasonably foreseeable exposure routes. In the toxicological profiles pursuant to Part A No. 8, the interaction between substances must be explicitly taken into account, and Part B No. 3 requires the assessment of possible interactions between the substances in the product.

The Scientific Committee SCCS sets the benchmark for dermal absorption. The SCCS Notes of Guidance in the 12th revision state that a formulation can influence the bioavailability of individual ingredients and that penetration enhancers are used deliberately. If experimental data on dermal absorption are lacking, a default value of 50 percent is assumed. According to the SCCS, there is currently no standard protocol for compromised skin; results on intact skin are preferred.

What this means for the briefing

  • Specify whether the booster is intended to be used only with products from your own line or with any subsequent products. A closed system can be evaluated specifically, whereas an open combination can only be assessed using conservative assumptions.

  • According to Art. 3, instructions for use are among the aspects under which safety is assessed. The order of application, quantity, and time interval before applying the subsequent product are therefore part of the assessment, not just marketing.

  • Substances in subsequent products whose absorption was evaluated on intact skin, such as retinoids or acids, should be re-examined for pre-treated skin. The decision is made by the safety assessor.

Which formulation problems are typical for boosters?

Typical problems depend on the booster type. What they all have in common is that testing the individual product alone is not sufficient.

Spicule boosters

Spicules are dense, insoluble particles. Without a sufficient yield point, they sediment in gel or serum, causing the content per application to fluctuate. The viscosity must therefore be adjusted so that the particles remain suspended while the product can still be dispensed from the packaging. For pump dispensers, dosing accuracy as well as valve and seal wear must be tested; during filling, homogeneity across the entire batch must be checked, not just in the mixing vessel.

Concentrates for mixing in

The actual product is only created upon mixing. The pH value, electrolyte content, and solvents of the concentrate can destabilize an emulsion or break a thickening system. In addition, the concentrate dilutes the preservative system of the base cream. The challenge test according to ISO 11930 assesses the preservation of the specifically tested formulation; the mixture of concentrate and base is not covered by this and should be evaluated separately if it can be stored for several days.

Primer layers

With primers, incompatibility often manifests sensorially: film formers and polymers in the primer and subsequent product can roll up during application (pilling), or the subsequent product absorbs less effectively or leaves a film behind. Therefore, sampling and sensory profile tests should always be conducted in the intended order of application. The scope of testing for stability and preservation is explained in the article on stability and safety testing for cosmetics.

Which advertising claims can be substantiated for a booster?

A booster claim is almost always a comparative statement: the subsequent product works better with the booster than without it. It is precisely this combination that must be substantiated. The Annex to Regulation (EU) No 655/2013 requires under the criterion of substantiation (Nos. 3.1 and 3.4) that claims must be supported by adequate and verifiable evidence and that the evidential value of the support matches the type of claim. According to the criterion of truthfulness (No. 2.2), claims about the properties of an ingredient must not imply that the finished product has the same properties if it does not.

Claim

What it claims

Suitable substantiation

“improves the absorption of your serum”

Penetration of a subsequent product

In vitro permeation study, for instance using a Franz diffusion cell, with and without booster

“enhances the effect of your skincare”

Effect of the combination

User trial with a comparison group without booster

“microneedling effect”

mechanical action in the skin

Penetration data on the finished product, clear distinction from the treatment

“with PDRN”

Presence of an ingredient

formulation and raw material specification

Raw material supplier studies on spicule penetration or PDRN do not automatically prove the efficacy of the finished formulation. The evidence must relate to the product and, in the case of booster claims, to the advertised combination. If the claim applies to any subsequent product, a study with a single serum is not sufficient. The current body of research on PDRN is discussed in the article on PDRN in cosmetics, while the general rules are summarized in the article on cosmetic advertising claims in the EU.

How does a booster project work at Labtree?

How does a booster project work at Labtree?

How does a booster project work at Labtree?

Labtree is a B2B cosmetics developer and cosmetics manufacturer from Hamburg with its own laboratory and production capacities in Germany. For a booster, Labtree covers formulation development, in-house laboratory work, sampling, manufacturability testing, and cosmetics production. For a booster system, this means: the booster and follow-on product can be developed in the same laboratory and sampled together, and the manufacturability of a particle suspension is tested during development, not only upon transfer to production scale.

  • Sampling: Samples of pre-qualified formulations usually leave the sample warehouse within 24 hours, allowing the combination to be evaluated on the product at an early stage.

  • Timeframe: In white label—i.e., based on a finished, tested Labtree formulation that is adapted for the brand and remains the property of Labtree—a product with standard packaging is generally ready for delivery in 2 to 3 months. A new development according to the brand's requirements under private label usually takes 3 to 6 months to reach market readiness.

  • Quantity: The minimum order quantity is generally 1,500 units per product, depending on the product type, filling size, and packaging. For a system consisting of a booster and a serum, it applies per product.

  • Documentation: Safety assessment and regulatory approval are included in the services; the intended combination with follow-on products should already be specified in the briefing for this purpose.

The page Have cosmetics developed describes the process from conception to production.

Quellen

FAQ

Is a skinbooster a cosmetic product?

Only when applied externally. According to Art. 2 (2) of Regulation (EC) No. 1223/2009, substances and mixtures intended to be injected are not considered cosmetic products; therefore, injectable skin boosters do not fall under the EU Cosmetics Regulation. A topical product with this name must not suggest the effects of an injection.

Can a spicule booster be advertised as having a microneedling effect?

Only if the claim is substantiated for the finished product and does not give the impression of a medical treatment. Raw material supplier studies generally only prove the efficacy of the raw material itself, and under Regulation (EU) No 655/2013, properties of an ingredient must not be presented as properties of the finished product if this is not the case. Claims regarding the improved absorption of a specific follow-up product are more objective and easier to substantiate.

Does a booster need to be tested with every possible follow-up product?

No, but the safety assessment must cover the intended and reasonably foreseeable use. A practical approach is to narrow the scope via the instructions for use, for example, by restricting it to products within the same line. The more open the combination, the more conservative the safety assessor's assumptions will be.

Does a booster require its own CPNP notification and Product Information File?

Yes. Every cosmetic product is notified in accordance with Article 13 of Regulation (EC) No 1223/2009 prior to being placed on the market, and pursuant to Article 11, the responsible person maintains a Product Information File for each product that includes the safety report. The process is outlined in the magazine article "EU Cosmetics Regulation in Practice: CPNP Notification, Product Information File, and Safety Report".

What role does PDRN play in booster products?

PDRN is frequently used as an active ingredient in primer serums that are applied before another serum. The known efficacy data mostly stems from injections and wound treatment; the study base for topical products is thin. The magazine article "PDRN in Cosmetics" classifies its origin, the study landscape, and formulation limits.

How long does it take to develop a booster?

Based on a finished, tested formulation under white label, a product with standard packaging is generally ready for delivery at Labtree within 2 to 3 months. A booster tailored to a specific follow-up product is usually a new development under private label, typically taking 3 to 6 months to reach market readiness. Combination tests and stability tests determine where within this timeframe the project lands.

From what quantity can a booster be produced?

At Labtree, the minimum order quantity (MOQ) is generally 1,500 units per product, depending on the product type, fill size, and packaging. For a system consisting of a booster and a serum, this applies separately to each product. The factors that generally determine minimum order quantities are explained in our magazine article "MOQ in Cosmetics Explained".

Subscribe to our newsletter

Get more helpful information about cosmetics development.

Subscribe to our newsletter

Get more helpful information about cosmetics development.

Subscribe to our newsletter

Get more helpful information about cosmetics development.

Now discover more articles

Contact us!

>